Confident sounding CEO gave a great overview of VOLC's current business and strong pipeline of new products to be launched over the next 6-18 months. Base business growing 15% annually, with VOLC growing 25%+ as it continues to take market share from Boston Scientific. VOLC continues to win 80% of new deals. New pipeline includes add-on to existing installed base of systems to provide 100x better imaging. VOLC has strong core business, several new products coming out, and $100 million of cash/no debt in which to make tuck-in acquisitions. 4400 installations worldwide. Full direct sales model with partnerships/sales push help by competitors' competition. So working with Medtronic and Abbott for example. Current biz is duopoly in IVUS vs. Boston Sci and vs. St. Jude in FFR wire. Remember St. Jude's sales came in lighter than expected. Well FFR market growing 20%+, but VOLC is seeing 70%+ growth as it gains share.
Overall, a very impressive presentation. Also, word is spreading about FAME and other study results showing a full one-third improvement in reducing heart attack risk using VOLC's products resulting in $700 per patient savings on average. A better tool that saves lots of money.
VOLC remains underloved, underfollowed and undervalued. This should be $20+ right now even in an uncertain health care environment as improving care and saving money works in any environment.